References in periodicals archive ?
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Among 62 people with HIV and persistently high liver enzymes--but without hepatitis virus infection--73% had nonalcoholic fatty liver disease (NAFLD), 55% had nonalcoholic steatohepatitis (NASH), and 18% had advanced fibrosis.
In the other study, researchers in France found that nonalcoholic steatohepatitis disappeared in 85 percent of obese patients one year after they had weight-loss surgery.
Key clinical point: Vitamin E was shown to improve nonalcoholic steatohepatitis (NASH) to an extent similar to those of pioglitazone, metformin, and obeticholic acid.
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.
The company's lead product, cenicriviroc, is a first in class immumodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of nonalcoholic steatohepatitis and HIV.
Ludwig of the Mayo Clinic named this condition of fatty liver changes in obese persons nonalcoholic steatohepatitis (NASH); it now is recognized as the inflammatory stage of NAFLD (Ludwig, Viggiano, McGill, & Oh, 1980).
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are hepatic phenotypes of metabolic syndrome.
New research suggests that estrogen protects women with nonalcoholic steatohepatitis (NASH) from severe liver fibrosis.
USPRwire, Tue Oct 01 2013] Nonalcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver.
Ronis stated that future studies would be designed to determine if MCT rich diets can reverse NAFLD and nonalcoholic steatohepatitis in disease models, and if successful, clinical trials may be initiated in patients with metabolic syndrome.
In contrast, up to 25% of patients may progress from simple steatosis to nonalcoholic steatohepatitis (NASH), which is characterized by necro-inflammation and/or varying degrees of fibrosis.
Customarily NAFLD had been regarded as a benign disease; however clinical as well as epidemiological studies have contradicted this belief and have shown that approximately 20% of the patients with NAFLD had Nonalcoholic steatohepatitis (NASH).